IHC STAIN CRITERIA FOR OBTAINING CLASS II STATUS OUTLINED BY FDA
This article was originally published in The Gray Sheet
Executive SummaryIHC STAIN CRITERIA FOR OBTAINING CLASS II STATUS OUTLINED BY FDA in a July 20 draft "points to consider" document on premarket requirements for immunohistochemical stains. FDA's proposal to classify IHC in vitro diagnostics as Class II devices will be discussed at an Aug. 5 meeting of the FDA Hematology and Pathology Advisory Panel and at an Aug. 19 meeting of the FDA Immunology Advisory Panel ("The Gray Sheet" July 25, In Brief).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.